Trifluridine-Tipiracil
Trifluridine-Tipiracil 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Advanced Microsatellite Stable Colorectal Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
25 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Gilead Sciences
- Delcath Systems Inc.
- Taiho Pharmaceutical Co., Ltd.
- Sun Yat-sen University
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Astellas Pharma Global Development, Inc.
- Crescent Biopharma, Inc.
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Czechia、德国、意大利、荷兰、Serbia、西班牙、Turkey (Türkiye)、英国、日本、中国、澳大利亚
正在招募患者的 Trifluridine-Tipiracil 研究
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
II 期招募中美国Czechia德国意大利NCT06607458AB122 Platform Study
I 期招募中日本NCT04999761Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
II 期招募中中国NCT05965531Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
III 期招募中中国NCT06992648A Study of ASP1002 in Adults for Treatment of Solid Tumors
I 期招募中美国NCT05719558CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
I 期 / II 期招募中美国澳大利亚法国爱尔兰NCT07335497Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
II 期招募中意大利NCT06522919Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer
不适用招募中挪威NCT07171554Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
I 期招募中美国NCT04920032Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer
III 期招募中法国NCT06197425Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
I 期 / II 期招募中中国台湾NCT05927857Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
II 期招募中美国NCT05806931A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
III 期招募中美国Argentina澳大利亚奥地利NCT07549412Second-line Treatment of Metastatic Colorectal Cancer
II 期招募中中国NCT06242067ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
I 期 / II 期招募中美国中国South KoreaNCT05405595ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"
II 期招募中意大利NCT07381764A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
III 期招募中美国比利时中国德国NCT07525206- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
II 期招募中奥地利德国NCT06856837Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
II 期招募中美国澳大利亚South Korea西班牙NCT07527858ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
早期 I 期招募中美国NCT07318389Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
II 期招募中中国NCT07085169Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
III 期招募中中国NCT06850090Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
I 期招募中美国法国意大利荷兰NCT03715933TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
II 期招募中中国NCT06293014
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。